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The prevalence of CD36 deﬁciency in East Asian and African populations suggests that the causal variants
are under selection by severe malaria. Previous analysis of data from the International HapMap Project indi-
cated that a CD36 haplotype bearing a nonsense mutation (T1264G; rs3211938) had undergone recent posi-
tive selection in the Yoruba of Nigeria. To investigate the global distribution of this putative selection event,
we genotyped T1264G in 3420 individuals from 66 populations. We conﬁrmed the high frequency of 1264G in
the Yoruba (26%). However, the 1264G allele is less common in other African populations and absent from all
non-African populations without recent African admixture. Using long-range linkage disequilibrium, we
studied two West African groups in depth. Evidence for recent positive selection at the locus was demon-
strable in the Yoruba, although not in Gambians. We screened 70 variants from across CD36 for an associ-
ation with severe malaria phenotypes, employing a case–control study of 1350 subjects and a family study of
1288 parent–offspring trios. No marker was signiﬁcantly associated with severe malaria. We focused on
T1264G, genotyping 10 922 samples from four African populations. The nonsense allele was not associated
with severe malaria (pooled allelic odds ratio 1.0; 95% conﬁdence interval 0.89–1.12; P 5 0.98). These results
suggest a range of possible explanations including the existence of alternative selection pressures on CD36,
co-evolution between host and parasite or confounding caused by allelic heterogeneity of CD36 deﬁciency.
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Erythrocytes infected with mature forms of the Plasmodium
falciparum parasite adhere to endothelium, platelets, leuco-
cytes and uninfected erythrocytes, a behaviour considered
key to the pathogenesis of severe falciparum malaria (1).
The majority of P. falciparum clinical isolates bind CD36
(1–4). A family of variant molecules called P. falciparum
erythrocyte membrane protein 1 (PfEMP1) is responsible for
binding CD36 and other host antigens (5). PfEMP1 is
expressed by the parasite onto the surface of infected red
blood cells (iRBCs) and is subject to switching during the
course of an infection. CD36 is found on a range of cell
types including platelets, dendritic cells and endothelium (6).
Adhesion of iRBCs to endothelial CD36 helps the parasite
avoid splenic passage, contributes to microcirculatory occlu-
sion and promotes local inﬂammatory responses (1).
CD36-mediated binding of iRBCs to dendritic cells inhibits
their maturation and function (7), and CD36 on platelets is
required for the formation of platelet-mediated clumps,
which are associated with severe disease (8).
CD36 deﬁciency (or Nak
a-negative blood group) has been
reported in Japanese (9), Thais (10) and African-Americans
(11). The prevalence of CD36 deﬁciency in East Asian and
African populations raises the possibility that the responsible
variants have been selected for by malaria. The molecular
basis of CD36 deﬁciency in African-Americans is distinct
from that found in East Asia (12). Common alleles reported
in East Asia include a proline to serine missense mutation at
codon 90 of the CD36 gene (C478T) and a frameshift mutation
at codon 317 (1159insA) (13). The commonest reported African
CD36 deﬁciency allele is a nonsense mutation in exon 10 of
CD36 (T1264G; rs3211938), which terminates the polypeptide
before the second transmembrane domain (12).
Further evidence that evolutionary selection has shaped
genetic variation at the CD36 locus emerged from phase 1 of
the International Haplotype Map (HapMap) project (14). The
HapMap project performed whole-genome high-resolution gen-
otyping in samples from four populations including 30 parent–
offspring trios from the Yoruba ethnic group from Ibadan in
southwestern Nigeria, 30 parent–offspring trios from Utah (of
northern and western European ancestry), 45 unrelated Han
Chinese from Beijing and 45 unrelated Japanese from Tokyo.
The CD36 nonsense allele, 1264G, was common in the
Yoruba (25%) but not detected in other populations. The
1264G allele was present on haplotypes found to be unusually
similar over hundreds of kilobases (see Supplementary
Material, Fig. S1). This signal, termed extended haplotype
homozygosity (EHH), suggested that 1264G had been under
recent positive evolutionary selection (15,16).
Genetic epidemiological studies of severe falciparum
malaria have examined whether CD36 deﬁciency alleles
affect susceptibility, but have not produced consistent
answers (Table 1). An initial case–control study of 1359
Gambian and Kenyan children found CD36 deﬁciency
appeared to be associated with susceptibility to severe
disease, leading the authors to propose that another infectious
pathogen was responsible for the frequency of CD36
deﬁciency in East Asians and Africans (12). In contrast, a
matched case–control study of 693 pairs of Kenyan children
found that 1264G heterozygotes were protected from
malaria, particularly from having multiple syndromes of
malaria (17). A third study of 223 children from Ibadan in
Nigeria was unable to detect a signiﬁcant difference in
T1264G frequency between children with severe disease and
those with asymptomatic parasitaemia (18). However, a
recent study of 913 Kenyan children has, once again,
suggested that 1264G is associated with susceptibility to
malaria (19).
We set out to analyse in detail the relationship between
CD36 variation and severe malaria. Our aims were as follows.
(i) Determine the distribution of the putative T1264G selec-
tion event in a range of African and non-African popu-
lations.
(ii) Replicate the CD36 EHH signal in the Yoruba and, if
possible, in additional populations.
(iii) Test single-nucleotide polymorphisms (SNPs) across
CD36 for associations with severe malaria. Previous
genetic association studies have focused on T1264G,
and only a fraction of variation across the gene has
been analysed. Other SNPs in or near CD36 may demon-
strate novel disease associations and could assist the ﬁne-
mapping of functional changes.
(iv) Employ a series of population- and family-based studies
of severe malaria phenotypes to reﬁne the risk estimate
associated with T1264G.
RESULTS
A global survey of CD36 haplotypes and T1264G
We genotyped the T1264G polymorphism in 3420 individuals
from 66 ethnic groups. These included 974 individuals from
the Human Genome Diversity Project (HGDP)-Centre
d’Etude du Polymorphisme Humain (CEPH) Diversity Panel
(51 ethnic groups) and 2446 additional Gambian, Malawian,
Kenyan and Ghanaian cord blood samples and population con-
trols (15 ethnic groups). The 1264G allele was at a frequency
of 26% in the Yoruba of Nigeria, a ﬁnding consistent with the
HapMap Yoruba (24.2%) and another recent study of Nigerian
children (18). The 1264G allele was present in populations
across sub-Saharan Africa, but was generally less frequent
than in the Yoruba (Fig. 1). The 1264G allele was not seen
in two African populations living in the regions of lower
malaria risk, the South African Bantu and the Namibian San.
However, their limited sample sizes may mean the allele is
present at low frequencies but undetected. The pygmies of
central Africa, such as the Biaka (Central African Republic)
and the Mbuti (Democratic Republic of Congo), are relatively
genetically isolated from other sub-Saharan populations. There
is, however, evidence that the Biaka have experienced admix-
ture with neighbouring groups (20). This is consistent with the
presence of 1264G alleles in the Biaka (5.8%) but not in the
Mbuti (0%). The 1264G allele was absent from almost all non-
African ethnic groups. The Makrani of Pakistan were the only
group outside of Africa (and the only Pakistani ethnic group)
to have 1264G (2.1%). The presence of 1264G is consistent
with past African admixture in the Makrani (21). For a full
2684 Human Molecular Genetics, 2009, Vol. 18, No. 14breakdown of samples genotyped and 1264G allele frequen-
cies, see Supplementary Material, Table S1.
We genotyped 53 additional SNPs, in and around CD36,i n
the HGDP-CEPH Diversity Panel. These markers comprised
12 intragenic SNPs (average density 1 SNP/6.3 kb) and 41
SNPs extending 300 kb up- and downstream of CD36
(average density 1 SNP/15.3 kb). We compared haplotypes
carrying 1264G with those bearing the ancestral 1264T, calcu-
lating the EHH surrounding the core SNP (T1264G) (see
Materials and Methods). EHH reﬂects the probability that
two haplotypes, chosen at random from a population, will
share identical markers, from the core SNP to a speciﬁed
test position. Haplotypes carrying the 1264G allele were
more similar over longer distances than those with the ances-
tral T-allele (Fig. 2), a common trend when comparing ances-
tral and derived alleles (22). Measured 100 kb upstream
from the core SNP (at rs1851937), the 1264G haplotype
EHH was still 1.0 compared with 0.117 for 1264T, while at
300 kb upstream (rs304775), 1264G EHH was 0.462
versus 0.026 for 1264T. Downstream, however, EHH values
were lower, and there was less difference between the two
haplotype subtypes; at 100 kb (rs12669309), EHH was
0.231 (G) versus 0.12 (T), and 0.064 (G) versus 0.006 (T) at
300 kb (rs2367090). To assess the signiﬁcance of these
differences, we measured relative EHH (REHH, the ratio
between EHH on haplotypes marked by 1264G and haplotypes
bearing the T-allele) at a distance of 0.25 cM from the core
SNP and compared these measurements with the empirical
genome-wide distribution of the long-range haplotype (LRH)
test (14)). The REHH was 17.6 (50) and 3.2 (30). In other
words, the EHH was 17-fold greater on haplotypes bearing
1264G at 0.25 cM upstream. This 50 value is .99th centile
compared with the empirical distribution of REHH and
similar to (or greater than) previous reports of alleles
under selection in Africans [e.g. G6PD deﬁciency, haplotype
Table 1. Published risk estimates of severe malaria phenotypes associated with CD36 deﬁciency alleles
Publication Population Cases Controls Phenotype Allele/genotype OR 95% CI P-value
Aitman et al. (2000)
(12)
Gambia and
Kenya
598 761 All cases def versus wt 1.53 1.09–2.15 0.01
a
(388)
b 761 CM def versus wt 1.49 1.01–2.20 0.04
(97) (331) CM GG versus rest — — 0.04
Pain et al. (2001) (17) Kenya 693 693 All cases GG and GT versus TT 0.74 0.55–0.99 0.036
a
(104) 693 Three or four syndromes GG and GT versus TT 0.47 0.22–0.95 0.024
(589) 693 One or two syndromes GG and GT versus TT 0.79 0.58–1.07 0.11
(413) 693 CM GG and GT versus TT 0.84 0.60–1.18 0.27
(250) 693 Respiratory distress GG and GT versus TT 0.67 0.43–1.04 0.051
(304) 693 SA GG and GT versus TT 0.62 0.41–0.94 0.017
(146) 693 Hypoglycaemia GG and GT versus TT 0.54 0.30–0.96 0.026
Amodu et al. (2005)
(18)
Nigeria 101 53 Uncomplicated versus
asymptomatic
G versus T — — 0.062
c
69 53 Severe versus asymptomatic G versus T — — 0.326
Ayodo et al. (2007)
(19)
Luo (Kenya) 456 457 All cases GT versus rest 1.5 1.03–2.18 0.03
456 457 All cases GG versus GT versus
TT
— — 0.061
456 457 All cases G versus T — — 0.0023
d
456 457 All cases G versus T — — 0.00043
e
OR, odds ratio; CI, conﬁdence interval; def, CD36 deﬁciency alleles 1264G and 1439C pooled; wt, CD36 wild-type allele; the remaining alleles and
genotypes refer to CD36 T1264G. CM, cerebral malaria; SA, severe anaemia; Severe, all severe cases; Uncomplicated, non-severe malaria.
aMantel–Haenszel stratiﬁed analysis.
bSample numbers in brackets refer to subsets of the studies’ cases or controls.
cMultivariate analysis.
dWeighted for population differentiation (Yoruba versus Masai).
eWeighted for population differentiation (Yoruba versus Kikuyu).
Figure 1. Frequencies of the CD36 1264G nonsense allele in a range of
African and Middle Eastern populations. For each population, the country of
origin, number of individuals samples and 1264G allele frequency are given
(in parentheses) as follows: 1, Fula, Jola, Mandinka, Manjago, Serehuli,
Serere and Wolloff (The Gambia, 582, 2%); 2, Mandenka (Senegal, 21,
0%); 3, Kasem, Nankan and Buli (Ghana, 737, 14%); 4, Yoruba (Nigeria,
25, 26%); 5, Biaka Pygmy (Central African Republic, 26, 5.8%); 6, Mbuti
Pygmy (Democratic Republic of Congo, 7, 0%); 7, northeastern Bantu
(Kenya, 11, 4.5%); 8, Chonyi, Duruma, Giriama and Kauma (Kenya, 722,
8.6%); 9, Malawians (Malawi, 405, 8.9%); 10, San (Namibia, 6, 0%); 11,
southeastern and southwestern Bantu (South Africa, 7, 0%); 12, Mozabite
(Mzab region of Algeria, 23, 0%); 13, Palestinian, Druze and Bedouin
(Israel, 138, 0%); 14, Sindhi, Pathan, Kalash, Hazara, Burusho, Brahui and
Balochi (Pakistan, 158, 0%); 15, Makrani (Pakistan, 24, 2.1%). The 1264G
allele is absent from all other populations assayed but not shown in this ﬁgure.
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was not signiﬁcant.
For comparison, we downloaded phased haplotypes from the
HapMap Yoruba, paring down the data set to the same 54 SNPs
(including T1264G) (Fig. 2). As expected, EHH measurements
were greater on 1264G haplotypes. Upstream EHH was, at
100 kb, 0.741 (G) versus 0.089 (T); at 300 kb, 0.571 (G)
versus 0.012 (T); downstream, at 100 kb, 0.483 (G) versus
0.129 (T); and at 300 kb, 0.227 (G) versus 0.005 (T). The
HapMap Yoruba had REHH values of 29.7 (50) and 14.6 (30)
[both .99thcentileandconsistentwiththeoriginalobservation
(14)]. REHH values for our HGDP Yoruba are lower than those
for the HapMap Yoruba, particularly downstream of T1264G.
There are a range of explanations for these differences: (i) the
HapMap data had a slightly lower missing genotype rate (1
versus 3% for HGDP); (ii) the HapMap haplotypes were
inferred from higher density marker data; (iii) our HGDP
sample size was smaller (50 haplotypes versus 120 HapMap
haplotypes); and (iv) the HapMap haplotypes were inferred
from parent–offspring trios. Offspring genotypes can be used
to unambiguously resolve phase at some parental markers. To
test the impact of phasing accuracy on EHH, we obtained
Yoruba genotypes from the HapMap project and phased them
without utilizing offspring data (treating the parents as 60 unre-
lated individuals). The resulting haplotypes had an REHH of
29.6 upstream, but only 5.1 downstream (Supplementary
Material, Fig. S2). This suggests that the asymmetry in HGDP
Yoruba REHH, between 50 and 30 regions, may reﬂect technical
artefacts affecting haplotype estimation downstream (e.g. assay
performance, phasing accuracy) rather than a biological signal
(e.g. selection acting on sequences upstream of T1264G).
Too few 1264G haplotypes were sampled from the Makrani,
the Biaka of the Central African Republic or the northeastern
Bantu for a valid assessment of EHH to be made. To study
1264G haplotypes in detail, we selected 101 parent–offspring
triosfromourGambianfamilystudy(seenextsection).Twenty-
six trios were selected because one or both parents had the
1264G allele. The remaining 75 were randomly chosen from
the family study. Samples were genotyped and analysed in a
manner similar to the HGDP-CEPH Diversity Panel. Offspring
genotypes were used to assist phasing. In total, 30 1264G
haplotypes were compared with 374 1264T haplotypes
(Fig. 2). EHH values on Gambian CD36 1264G haplotypes
were raised. Upstream EHH was, at 100 kb, 0.405 (G)
versus0.082(T);at 300 kb,0.184(G)versus0.006(T);down-
stream,at 100 kb,0.607(G)versus0.114(T);andat 300 kb,
0.122 (G) versus 0.003 (T). REHH was 19.1 upstream and 12.8
downstream. However, EHH is often raised around low fre-
quency, derived alleles. The signiﬁcance of these results was
determined using phased genome-wide SNP data from 658
Gambian parent–offspring trios genotyped on an Illumina
650Y BeadArray platform (manuscript in preparation). The
offspring in these trios were malaria cases; so to minimize
bias, we analysed only untransmitted parental chromosomes.
WecalculatedtheREHHfor15 807derivedallelesoffrequency
1–3%, where REHH could be assessed at 0.25+0.01 cM from
the core SNP. Comparison with this empirical, genome-wide
distribution of the LRH test suggests our Gambian REHH
values are not signiﬁcantly unusual, 59th centile (12.8) and
77thcentile(19.1).Thisﬁndinghighlightsthatlow-frequency
alleles are often surrounded by long haplotypes, limiting the
power of EHH testing.
Genetic association studies with severe malaria phenotypes
Seventy CD36 SNPs, including T1264G and G1439C [a mis-
sense mutation in strong linkage disequilibrium in Gambians
with the 1444delA frameshift mutation, another CD36
deﬁciency allele (12)], were tested for disease associations
in Gambian case–control and family studies (see Material
and Methods for further details of SNP selection). The
family study comprised 1288 children affected by severe
malaria and both parents [these trios included 508 cases of cer-
ebral malaria (CM) and 333 cases of severe malarial anaemia
(SA)]. The case–control study was separate from the family
study and comprised 727 cases of severe malaria (339 CM,
226 SA) and 623 population controls. Both studies were
powered to detect realistic effect sizes at a signiﬁcance
threshold of P , 0.05. Only one marker, rs4728191, an intro-
nic SNP, exceeded this threshold in both studies. The minor
allele was associated with protection on both occasions
Figure 2. EHH decay surrounding T1264G in HGDP Yoruba, HapMap
Yoruba and Gambian trios. Breakdown of extended haplotype homozygosity
(EHH) with distance, on haplotypes partitioned by the alleles of T1264G
(rs3211938; the ‘core’ SNP). We compared (A) 25 HGDP-CEPH Yoruba indi-
viduals, (B) HapMap genotypes from 60 Yoruba parents and (C) 202 Gambian
parents.
2686 Human Molecular Genetics, 2009, Vol. 18, No. 14[case–control, severe malaria, allelic odds ratio (OR) 0.76;
95% conﬁdence interval (CI) 0.61–0.96, P ¼ 0.019; family
study, SA, allelic OR 0.70; 95% CI 0.5–0.99, P ¼ 0.041].
This ﬁnding needs cautious interpretation, as the associations
were with different phenotypes and the Hardy–Weinberg
P-value for rs4728191 in cord blood controls was marginal
(P ¼ 0.006). All results from the case–control and family
studies with P , 0.05 are documented in Supplementary
Material, Table S2.
Using the UNPHASED application, we combined the case–
control and family data into a single analysis (Fig. 3). Given
that 70 SNPs have been tested, the formal signiﬁcance
threshold, with conservative Bonferroni correction, would be
roughly 0.0007 (0.05/70). No marker in CD36 had P ,
0.002 for any genetic model or phenotype. Rs4728191 was
not signiﬁcantly associated with severe malaria phenotypes
in the combined analysis (severe malaria, allelic OR 0.89;
95% CI 0.79–1.01, P ¼ 0.06; SA allelic OR 0.84; 95% CI
0.67–1.06, P ¼ 0.13). Neither T1264G (severe malaria,
allelic OR 0.93; 95% CI 0.67–1.29, P ¼ 0.65), nor G1439C
(severe malaria, allelic OR 0.90; 95% CI 0.68–1.19, P ¼
0.46), nor both deﬁciency alleles considered together (severe
malaria, allelic OR 0.91; 95% CI 0.73–1.13, P ¼ 0.39)
were signiﬁcantly associated with severe malaria phenotypes.
Complete results from the pooled analysis are documented in
Supplementary Material, Table S3.
Given the previous report of protection associated with
1264G heterozygotes (17), we speciﬁcally checked for such
an effect. Deﬁciency allele heterozygotes did tend to be under-
represented among cases (versus wild-type homozygotes, OR
0.83; 95% CI 0.66–1.05). In addition, no CD36-deﬁcient indi-
vidual (e.g. 1264G homozygote, 1439C homozygote or com-
pound heterozygote) was found among the 727 cord blood
controls, although several were seen among the cases (three
in the case–control study and eight in the family study)
(deﬁciency allele homozygotes versus wild-type homozygotes
OR 1.59; 95% CI 0.74–3.39). Together these results suggested
a non-signiﬁcant trend towards heterozygote advantage
(overdominant model P ¼ 0.09). However, the low frequency
of 1264G (1.9%) and 1439C (1.8%) in Gambians limited the
statistical power. To increase the power, we genotyped
T1264G and G1439C in ﬁve further sample sets derived
from populations where 1264G is more common (8.2% in
Kenyan controls, 9.0% in Malawian controls and 14.2% in
Ghanaian controls). These additional studies comprised:
(i) 718 Malawian cases and 405 controls (640 CM, 101 SA);
(ii) 708 Kenyan cases and 902 controls (216 CM, 270 SA);
(iii) 225 Malawi trios (216 CM, 39 SA);
(iv) 234 Kenyan trios (114 CM, 85 SA);
(v) 792 Ghanaian cases and 806 controls (44 CM, 296 SA).
The 1439C allele was at a frequency of 0.1% in Ghanaian
controls, but absent in Kenya and Malawi.
T1264G was not associated with severe malarial phenotypes
in the additional ﬁve studies individually. Pooling data across
all seven studies (5681 cases and controls, and 1747 nuclear
family trios) using the UNPHASED application, we found
no association between T1264G (severe malaria, allelic OR
1.0; 95% CI 0.89–1.12, P ¼ 0.98) or deﬁciency alleles
(1264G and 1439C pooled, severe malaria, allelic OR 0.98;
95% CI 0.89–1.09, P ¼ 0.76) and severe malaria (Table 2).
The putative trend towards a heterozygous advantage,
suggested by the Gambian data, was not supported by this
larger data set (deﬁciency allele heterozygotes versus wild-
type homozygotes, OR 0.97; 95% CI 0.86–1.09; deﬁciency
allele homozygotes versus wild-type homozygotes, OR 1.09;
95% CI 0.74–1.6; overdominant model P ¼ 0.53) (Table 3).
DISCUSSION
We set out to analyse the distribution of 1264G haplotypes in a
range of global populations, to screen variation across the gene
for association with severe malaria and to target 1264G with
well-powered tests of disease association. It is important to
stress that the initial observation of raised EHH on 1264G
Figure 3. P-values for the pooled Gambian case–control and family studies. Allelic model P-values derived from UNPHASED analysis of 70 SNPs across
CD36, for severe falciparum malaria (Severe), and the subphenotypes of cerebral malaria (CM) and severe malarial anaemia (SA). The arrow marks the position
of T1264G (rs3211938). Chromosome 7 coordinates from NCBI build 36/dbSNP 126.
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discussion of its biological signiﬁcance (14,16). This study
represents the ﬁrst detailed description of the CD36 EHH
signal found in the HapMap Yoruba. In addition, we presented
novel data from the HGDP collection exploring the frequency
of the nonsense allele across Africa and replicating the EHH
signal in the Yoruba. Our association study of severe
malaria and T1264G employed a sample size more than
twice that of all previous studies combined (Table 1). Given
our relative statistical power, the marginal signiﬁcance of
past results and their inconsistent outcomes, our data suggest
that CD36 T1264G is not associated with severe malaria. Fur-
thermore, no CD36 marker tested appeared to be signiﬁcantly
associated with disease susceptibility.
The reason for the expansion of the 1264G allele in West-
Central Africa is unclear. Nigeria has a high prevalence of
malaria infection, however, so does the Gambia (1264G fre-
quency 2%) and costal regions of Kenya (9%). The high fre-
quency in Nigeria might indicate a recent origin for the
allele in that region with subsequent migration. The lower
allele frequency outside Nigeria could simply reﬂect selective
sweeps in progress, but at earlier stages. There are a range of
plausible explanations for the presence of selection in the
absence of a malaria association. It is possible that the
signal of selection detected around 1264G could be spurious;
or that host–parasite co-evolution has eliminated the advan-
tage of this allele, subsequent to an initial selective sweep.
Alternatively, the failure to detect an association might rep-
resent type II error. The 1264G allele could provide a
modest degree of protection from severe malaria (e.g. an OR
between 0.95 and 1); protect from an infrequent but life-
threatening malaria phenotype; or only offer protection to
the rare deﬁciency allele homozygotes. This association
study would have only limited power to detect an effect in
these situations. A small effect size might be sufﬁcient to
maintain the allele at low frequency in populations. Hypothe-
tically, the expansion of 1264G alleles in the Yoruba could
represent a local selection event on top of a low-level back-
ground of selection by malaria. The additional Yoruba event
could also be malaria-related, for example the effects of a P.
falciparum strain speciﬁc to southwestern Nigeria. However,
CD36 operates in a range of key biological processes includ-
ing thrombostasis (23), glucose metabolism (24), lipid hand-
ling (25), immune function (26), angiogenesis (27) and
possibly taste (28). Therefore, other environmental factors
need to be considered as selective pressures.
Combining evidence for natural selection with disease
association statistics has been proposed as a technique to
increase power to detect disease associations. Our data high-
lights a potential pitfall for this approach. In recently pub-
lished work, an association between T1264G and severe
malaria (P ¼ 0.03) was combined with the substantial allele
frequency difference between the Yoruba (a population
exposed to endemic malaria) and the Kikuyu and Masai (popu-
lations at low malaria risk). The combined P-values reported
were highly signiﬁcant (up to P ¼ 0.00043) (19). However,
as we have seen, there is a substantial T1264G allele fre-
quency difference between the Yoruba and most African
populations, including others exposed to endemic malaria.
This highlights the possibility that marginal evidence of a
genetic association with disease A (e.g. severe malaria)
could be conﬂated with strong evidence of natural selection
caused by an unrelated process B (e.g. a novel dietary
source). Combined analysis remains an exciting approach,
but ensuring a signal of selection relates to the same disease
as association data (or gauging the degree of conﬁdence)
will be a challenge.
It is possible that CD36 deﬁciency alleles cause deleterious
consequences, particularly in the homozygous state, that
balance any hypothetical advantages. These include neonatal
immune thrombocytopenia (29), altered aerobic exercise
capacity (30) and dysregulation of lipid metabolism (25).
There is also, ironically, evidence that absence of CD36 is dis-
advantageous to the host during malaria infection. IRBCs are
recognized and phagocytosed by monocytes and macrophages
following CD36 binding (31,32). One disease association
study based in Thailand (475 adult patients with severe or
mild malaria) reported an intronic dinucleotide repeat allele
in CD36 [in3(TG)12] associated with protection from severe
malaria (33). The authors showed that other alleles of the
same microsatellite were associated with the production of a
short CD36 isoform altering the P. falciparum-binding
epitope. In contrast, the protective in3(TG)12 allele was associ-
ated with a full-length transcript, leading the authors to
suggest that iRBC binding to intact CD36 could facilitate efﬁ-
cient clearance. The majority of P. falciparum isolates bind
CD36 (1–4) yet only a fraction of infections lead to life-
threatening consequences. In vitro binding studies suggest
that parasite strains from asymptomatic controls with parasi-
taemia have high levels of CD36 binding, whereas strains
from individuals with non-severe, uncomplicated disease
have moderate levels of CD36 binding. The lowest levels of
CD36 binding are found in isolates from individuals with
severe phenotypes such as CM, and particularly SA
(2,3,34,35). CD36 (also known as fatty acid translocase) is
highly expressed in adipose tissue and skeletal muscle (6).
Absence of CD36 as a target for sequestration on these large
capillary beds may promote splenic passage and clearance of
CD36-binding parasites. This could select for parasite clones
which have switched to alternative host ligands. Post-mortem
Table 2. Estimated risk for CD36 T1264G in severe malaria
Population Cases Controls OR 95% CI P-value
Population-based studies
Gambia 727 623 0.74 0.4–1.37 0.34
Malawi 718 405 0.91 0.67–1.25 0.57
Kenya 708 902 1.20 0.93–1.55 0.15
Ghana 792 806 1.05 0.86–1.29 0.63
Family-based studies
Gambia 1288 2576 0.92 0.59–1.45 0.73
Malawi 225 450 1.00 0.62–1.62 1.00
Kenya 234 468 0.86 0.55–1.34 0.50
Pooled 4692 6230 1.00 0.89–1.12 0.98
Allelic odds ratios (OR) and 95% conﬁdence intervals (CI) for CD36
1264G compared with the T-allele, in severe malaria. P-values were
derived from logistic regression analysis with covariates of ethnic group,
gender and HbS genotype (population-based studies), case–
pseudo-control analysis (family studies) or UNPHASED analysis (pooled
data across all studies).
2688 Human Molecular Genetics, 2009, Vol. 18, No. 14immunohistochemistry studies show relatively low expression
of CD36 on brain endothelium without increased expression
during malaria (1,36). In contrast, other host ligands of
PfEMP1, such as intercellular adhesion molecule-1 and
E-selectin, are commonly expressed on cerebral endothelium
and induced by inﬂammation (36,37).
CD36 deﬁciency alleles have been reported to modulate
expression in a tissue-speciﬁc way. Some variants prevent
expression on platelets (CD36 deﬁciency type II), whereas
other alleles abolish CD36 expression on a wider range of
cellsincludingplatelets,macrophages,monocytesandprobably
other cell types (type I) (38,39). The 1264G allele is considered
tobeatypeIallele,butlittleisknownaboutexpressionpatterns
(ifany)onnon-haematopoieticcells.InadditiontoT1264Gand
1444delA, a range of CD36 deﬁciency alleles have been
reported in populations of African origin. These include
990delG and 1530ins14bp (12). Sequencing in Gambians has
suggested that 1264G and 1444delA are the commonest
deﬁciencyallelesinthispopulation,withothersbeing ,1%fre-
quency (12). However, caution is required when extrapolating
these ﬁndings across Africa. Allelic heterogeneity, particularly
whenunrecognized, has the potential to impair power in associ-
ation analysis (40,41) and could also be complicating our popu-
lation genetic study. The frequency distribution of CD36
deﬁciency across Africa could be quite different than suggested
by typing just 1264G and 1439Cþ1444delA. Resequencing of
CD36 in a range of African and Asian populations is needed to
describethefullrepertoire andgeographicdistributionofCD36
deﬁciency alleles.
In conclusion, the relationship between CD36 and malaria is
complex. The putative selection event associated with the
CD36 1264G nonsense allele appears to be focused in West-
Central Africa, although this and other CD36 deﬁciency
alleles are present across sub-Saharan and Asian populations.
A number of factors may explain the lack of an association
between CD36 variation and severe malaria phenotypes.
However, the existence of alternative (or additional) selection
pressures on CD36 deﬁciency alleles is an interesting possi-
bility that needs further investigation. Additional ﬁeld- and
in vitro work is required to deﬁne the phenotypic conse-
quences of CD36 deﬁciency alleles in health and disease.
MATERIALS AND METHODS
Human Genome Diversity Panel
Sample preparation and genotyping. DNA was derived from
lymphoblastoid cell lines of 1064 individuals from the
HGDP-CEPH Diversity Panel (http://www.cephb.fr/
HGDP-CEPH-Panel/) (42). Samples from 15 known duplicate
and atypical individuals were excluded (43). Genotyping was
performed using Sequenom iPLEX assays. SNP identiﬁers,
coordinates and genotyping success rates are documented in
Supplementary Material, Table S4. Following quality control
for missing genotypes, a set of 974 individuals were selected
for further analysis (average genotyping success rate 96.7%;
rs3211938 success rate 99.8%).
Statistical analysis. Phased haplotypes and missing data were
inferred using PHASE (version 2.1) (44,45). Genotype data
from each population was phased on its own. EHH calcu-
lations were performed using a web-based calculator (http://
ihg2.helmholtz-muenchen.de/cgi-bin/mueller/webehh.pl).
REHH was assessed as described previously (15,46). REHH
was assessed both sides of the core SNP (50 and 30). The
average REHH values for the two markers closest to
and either side of 0.25 cM were used for the LRH test
Table 3. Pooled analysis of CD36 deﬁciency alleles and severe malaria phenotypes
Phenotype Marker Genotype OR 95% CI rec over dom allelic
Severe T1264G GT versus TT 1.00 0.88–1.14 — — — —
— GG versus TT 0.98 0.64–1.52 — — — —
0.94 0.99 0.99 0.98
def het versus wt 0.97 0.86–1.09 — — — —
— hom versus wt 1.09 0.74–1.61 — — — —
0.62 0.53 0.64 0.76
SA T1264G GT versus TT 1.05 0.86–1.28 — — — —
— GG versus TT 0.79 0.35–1.74
0.53 0.62 0.75 0.89
def het versus wt 1.05 0.87–1.27 — — — —
— hom versus wt 0.89 0.43–1.84 — — — —
0.76 0.60 0.67 0.75
CM T1264G GT versus TT 1.09 0.91–1.31 — — — —
— GG versus TT 0.78 0.37–1.64 — — — —
0.47 0.34 0.45 0.60
def het versus wt 1.03 0.87–1.22 — — — —
— hom versus wt 1.03 0.55–1.93 — — — —
0.95 0.74 0.73 0.74
Pooled analysis performed from our seven studies using the UNPHASED application. Phenotypes: Severe, severe falciparum malaria; SA, severe
malarial anaemia; CM, cerebral malaria. Markers: T1264G or both CD36 deﬁciency (def) alleles pooled (G1439C þ 1444delA and T1264G). T1264G
genotypes: GG, 1264G homozygotes; GT, heterozygotes; TT, 1264T homozygotes; het, deﬁciency allele heterozygotes; hom, deﬁciency allele
homozygotes; wt, wild-type homozygotes; OR, odds ratio; CI, conﬁdence interval; P-values are reported for four genetic models rec(essive),
over(dominant), dom(inant) and allelic.
Human Molecular Genetics, 2009, Vol. 18, No. 14 2689[50, rs704871 (0.267 cM) and rs2944398 (0.225 cM); 30,
rs10487878 (0.236 cM) and rs4731861 (0.325 cM)].
Genetic association studies
Phenotype deﬁnition. All cases were children admitted to hos-
pital with evidence of P. falciparum on blood ﬁlm and clinical
features of severe malaria (47,48). We used a Blantyre coma
score of  2 as a criterion of CM (because of the limitations
of the available data, we used  3 in Ghanaian cases) and
,5 g/dl or packed cell volume ,15% as a criterion of SA.
Some individuals had both CM and SA. Of the severe
malaria cases that were not CM or SA by these criteria,
most had lesser degrees of coma (Blantyre coma score 3) or
anaemia (haemoglobin 5–6 g/dl), or other complications
such as respiratory distress. In Gambia, Malawi and Kenya,
controls were cord blood samples obtained from birth clinics
in the same locations as the cases. Ghanaian controls were
community controls matched for age, ethnic group and
location of origin.
Subjects. Patient samples were collected during ongoing epi-
demiological studies of severe malaria at the Royal Victoria
Hospital, Banjul, The Gambia; the Queen Elizabeth Central
Hospital, Blantyre, Malawi; Kiliﬁ District Hospital, Kiliﬁ,
Kenya; and Navrongo War Memorial Hospital, Ghana. All
DNA samples were collected and genotyped following
approval from the relevant research ethics committees and
informed consent from participants. See Supplementary
Material, Table S5, for demographic details of patients and
controls.
Power calculations. Power calculations were performed using
the Genetic Power Calculator (http://pngu.mgh.harvard.edu/
~purcell/gpc/) (49). For a type I error rate of 0.05, the
Gambian case–control and family studies had 85.7 and
98.7% power, respectively. This is based on an allelic OR of
1.3 and a high-risk allele frequency of 0.25 (the average
minor allele frequency of the SNPs screened in the Gambians).
With lower allele frequencies (0.1, 0.05 and 0.01), the case–
control studies (each roughly 700 cases and 700 controls)
had lower power, 59.1, 36 and 11.4%, respectively. The
additional family studies (approximately 250 trios) each had
25.8, 16.0 and 7.2% power. The power of the combined
case–control study (2945 cases and 2736 controls) was 99.3,
89.6 and 31.5%. The combined family study (1747 trios)
had 93.3, 71.6 and 21.3% power.
SNP selection. SNP data from HapMap release 21a (January
2007, http://www.hapmap.org) within 10 kb of the CD36
gene was downloaded and assessed using HAPLOVIEW
(version 3.32) (50). Polymorphic SNPs (minor allele fre-
quency .5%) were identiﬁed in the HapMap Yoruba.
Tagging SNPs were deﬁned using the TAGGER algorithm
(51). Sequenom iPLEX genotyping assays were designed for
69 tagging SNPs and three additional variants, T1264G,
G1439C and rs3173798 (located at a conserved splice site).
Following quality control, 70 SNPs were accepted for associ-
ation analysis. This ﬁnal set of SNPs tagged 116 of 133
(87%) polymorphic markers (.5% frequency) across CD36
(including 10 kb up- and downstream), using pairwise tagging
and an r
2 .0.8 (mean r
2 ¼ 0.97), in the HapMap Yoruba.
Sample preparation and genotyping. Genomic DNA samples
used in the association analysis underwent whole-genome
ampliﬁcation through either primer extension pre-
ampliﬁcation (52) or multiple displacement ampliﬁcation
(53), before Sequenom iPLEX genotyping. Genotype data
underwent quality control for missing data (,10%), Hardy–
Weinberg equilibrium (P . 0.001) and Mendelian error rate.
Genotype counts and quality control measures are documented
in Supplementary Material, Table S6.
Statistical analysis. Case–control association analysis was
performed by logistic regression using covariates of ethnic
group, gender and haemoglobin S (HbS) status. Sequenom
genotyping for the HbS variant was performed for all
samples as described previously (54). Family-based associ-
ation analysis was performed using a case–pseudo-control
approach and conditional logistic regression based on parental
genotypes. Trios were drawn from a larger pool of samples
assessed for relationship misspeciﬁcation by Mendelian error
rates. We utilized the R statistical application (version 2.6.0)
along with the dgc.genetics library (http://
www-gene.cimr.cam.ac.uk/clayton/software/) and the SNPas-
soc package (55). In both family- and population-based
studies, we tested each marker in allelic (or ‘multiplicative’),
dominant, recessive and overdominant (or ‘heterozygote
advantage’) genetic models and with three phenotypes (CM,
SA and all severe cases). Pooling across case–control and
family studies was performed using the UNPHASED appli-
cation (version 3.0.12) (http://www.mrc-bsu.cam.ac.uk/
personal/frank/software/unphased/) (56). Ethnic origin was a
signiﬁcant confounder and was retained as a covariate in the
UNPHASED analysis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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